Aveed (testosterone undecanoate) drug profile, 2024?

Question

Accepted Answer

Aveed (Testosterone Undecanoate) – 2024 Drug Profile

Item	Information
Brand Name	Aveed
Generic Name	Testosterone undecanoate
Drug Class	Anabolic–androgenic steroid; intramuscular testosterone ester
Formulation	100 mg/mL, 2 mL (200 mg) intramuscular injection in sesame oil (suspension).
Indication	Male hypogonadism (low testosterone) – symptomatic adults who cannot or prefer not to use other testosterone formulations.
Approved Age	≥18 years (FDA)
Key Clinical Trial	2021 FDA approval based on two multicenter, double‑blind, placebo‑controlled trials (≥2 yrs) showing significant improvement in serum testosterone, symptoms, and safety.

Feature	Details
Mechanism of Action	Intramuscular depot of testosterone undecanoate is slowly hydrolyzed to testosterone. Testosterone binds androgen receptors → regulates gene transcription, protein synthesis, libido, muscle mass, bone density, erythropoiesis.
Pharmacokinetics	• Absorption: Delayed release from intramuscular depot; peak serum testosterone ≈ 2–4 weeks after injection. • Distribution: High protein binding (~90 % to albumin). • Metabolism: Liver → 5α‑reductase → dihydrotestosterone (DHT), 5β‑reductase → 5β‑DHT; glucuronidation & sulfation. • Elimination: Urinary and fecal excretion; half‑life of depot ~36 days.
Therapeutic Range	300–1 000 ng/dL (12.4–41 nmol/L) for men; target set by clinician.
Dose‑Response	Linear relationship in therapeutic range; higher doses increase peak testosterone but plateau due to receptor saturation.

Step	Instruction
Initial Dose	200 mg IM (2 mL) into gluteus maximus or vastus lateralis.
Maintenance	200 mg IM every 10–14 weeks (≈ 3 months). Some clinicians extend to 12 weeks (≈ 3 months) based on serum levels.
Route	Intramuscular injection only (no oral, transdermal, or subcutaneous forms).
Administration Tips	• Rotate injection sites. • Use a 23–25 G needle; inject slowly. • Aspirate to avoid intravascular injection.
Missed Dose	If > 6 weeks missed: restart at initial dose; then maintenance interval.
Drug Interaction with Estrogens	Concomitant estrogen therapy may alter testosterone levels; monitor.

Category	Specifics
Absolute	• Known hypersensitivity to testosterone undecanoate or any component. • Untreated benign prostatic hyperplasia (BPH) or prostate cancer.
Relative	• Severe hepatic impairment (Child‑Pugh B/C). • History of thromboembolic disease, uncontrolled hypertension, or hyperlipidemia. • Severe cardiovascular disease (recent MI or stroke <6 mo).

Warning	Key Points
Cardiovascular	Testosterone may increase red blood cell mass, blood pressure, LDL/HDL ratio; monitor CBC, lipids, BP.
Prostate	May stimulate prostate growth; PSA and digital rectal exam (DRE) every 6 mo if baseline abnormal.
Hepatic	Monitor liver enzymes (ALT/AST) at baseline and every 3 mo.
Gynecomastia	Rare; treat with aromatase inhibitors if symptomatic.
Mood & Behavior	Possible mood swings, irritability; discuss with patient.
Breast Cancer Risk	Not fully understood; evaluate family history.
Sleep Apnea	Testosterone can worsen; screen patients with risk factors.

Category	Incidence (Phase III, 2021)
Injection Site	Pain (12 %), erythema (4 %), swelling (2 %).
Androgenic	Acne (6 %), alopecia (2 %), increased body hair (4 %).
Gastro‑intestinal	Nausea (1 %).
Hematologic	Polycythemia (5 %); monitor hematocrit.
Other	Headache, dizziness, edema (≤ 3 %).

Drug/Class	Interaction
Aromatase inhibitors (e.g., anastrozole)	Reduce estrogen conversion; may increase free testosterone.
CYP3A4 inducers (e.g., rifampin, carbamazepine)	Accelerate testosterone metabolism; lower serum levels.
CYP3A4 inhibitors (e.g., ketoconazole)	Decrease metabolism; increase serum testosterone → potential toxicity.
Statins	Testosterone may modestly lower LDL; monitor lipids.
Anticoagulants	No direct interaction, but testosterone may raise clotting tendency.

Population	Guidance
Older Adults (≥65 y)	Monitor cardiovascular status, cognition, and bone density.
Pregnancy/Lactation	Contraindicated – testosterone is teratogenic and can pass into breast milk.
Patients with BPH	Avoid unless under strict monitoring; consider alternative testosterone formulations with lower androgenic activity.
Patients with Hyperprolactinemia	Evaluate prolactin levels; testosterone may mask symptoms.
Patients with Hepatic Disease	Prefer lower maintenance doses; monitor liver function.
Patients on Antiviral Therapy (e.g., HIV)	Potential interactions via CYP3A4; adjust dose and monitor.

Pregnancy: Contraindicated. Testosterone can cause feminization of male fetus (cryptorchidism, hypospadias).
Lactation: Contraindicated. Testosterone is secreted into breast milk; can affect infant growth and development.

Overdose Signs: Excessive androgenic effects (acne, hirsutism, mood changes), erythrocytosis, hypertension, tachycardia.
Management: No specific antidote. Symptomatic treatment; monitor vitals, hematocrit, and electrolytes. If severe, discontinue therapy and consider hormonal assays.

Parameter	Frequency	Rationale
Serum Total Testosterone	At baseline, 6 weeks post‑dose, then every 4–6 weeks.	Ensure within therapeutic range and avoid supratherapeutic levels.
Hematocrit & Hemoglobin	Every 3 months.	Detect polycythemia early.
Liver Function Tests (ALT/AST, ALP)	Every 3 months.	Monitor hepatic toxicity.
Lipid Profile	Every 6 months.	Testosterone can alter lipids.
PSA & DRE	Every 6 months if prostate disease present or PSA > 4 ng/mL.	Detect potential prostate stimulation.
Blood Pressure & Weight	At each visit.	Identify cardiovascular risk.
Mood/Behavior	Ongoing.	Screen for androgenic mood changes.
Sleep Quality	At each visit for at-risk patients.	Testosterone may worsen OSA.

Injection Technique: Show correct intramuscular injection; explain site rotation.
Expected Benefits: Improved libido, energy, muscle mass, mood.

Ask Questions, Get Industry Insights … Instantly